CSIMarket
 
Elite Pharmaceuticals Inc   (ELTP)
 
Price: $0.2898 $0.00 -0.069%
Day's High: $0.2919999957084656 Week Perf: -0.07 %
Day's Low: $ 0.29 30 Day Perf: -23.74 %
Volume (M): 48,499 52 Wk High: $ 0.72
Volume (M$): $ 0 52 Wk Avg: $0.45
Open: $0.29 52 Wk Low: $0.27



 Market Capitalization (Millions $) 330
 Shares Outstanding (Millions) 1,138
 Employees 65
 Revenues (TTM) (Millions $) 147
 Net Income (TTM) (Millions $) 45
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 1

Business Description


Elite Pharmaceuticals Inc. is a global pharmaceutical company that focuses on the development, manufacturing, and commercialization of generic and branded pharmaceutical products. The company has a strong presence in the US, Europe, and Asia, with the majority of its business coming from the United States. Elite Pharmaceuticals has been in operation since 1984 and is headquartered in Northvale, New Jersey.

One of the primary areas of focus for Elite Pharmaceuticals is controlled-release drug delivery systems. The company has developed a proprietary technology that allows for the controlled release of drugs over an extended period of time. This technology has been applied to a wide range of drugs, including opioids for pain management, ADHD medications, and other therapeutics.

Elite Pharmaceuticals manufactures its products through its wholly-owned subsidiary, Elite Laboratories Inc. The company has a state-of-the-art manufacturing facility in Northvale, New Jersey, which is approved by the US Food and Drug Administration (FDA) and has been audited by regulatory agencies in Europe and Asia.

In addition to its focus on controlled-release drug delivery systems, Elite Pharmaceuticals also has a pipeline of new products in development. The company collaborates with other pharmaceutical companies and research institutions to develop new therapeutics for a variety of indications.

Elite Pharmaceuticals has a strong track record of commercial success. The company has a portfolio of more than 20 products under various stages of development and has successfully launched several products in the US market. Elite Pharmaceuticals has also received numerous accolades and awards for its innovative drug delivery systems and manufacturing capabilities.

The company's leadership team is led by CEO and President, Nasrat Hakim, who has over 30 years of experience in the pharmaceutical industry. The company also has a team of experienced executives, scientists, and engineers who are dedicated to advancing Elite Pharmaceuticals' mission of improving human health through innovative drug delivery systems.


   Company Address: 165 Ludlow Avenue Northvale 7647 NJ
   Company Phone Number: 750-2646   Stock Exchange / Ticker: ELTP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
RMTI        5.19% 
NEPH   -2.95%    
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 9.66
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.24
Price to Sales (Expected) -
Price to Book 3.34
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.72
Working Capital Ratio 6.45
Leverage Ratio (MRQ) 0.4
Total Debt to Equity 0.02
Interest Coverage (TTM) 377.56
Debt Coverage (TTM) 26.26

Per Share Current
Earnings (TTM) 0.03 $
Revenues (TTM) 0.13 $
Cash Flow (TTM) 0.01 $
Cash 0.03 $
Book Value 0.09 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,261,543
Net Income per Employee (TTM) 690,349
Receivable Turnover Ratio (TTM) 3.17
Inventory Turnover Ratio (TTM) 3.43
Asset Turnover Ratio (TTM) 1.14

Profitability Ratios Current
Gross Margin (MRQ) 50.98 %
Operating Margin (MRQ) 25 %
Net Margin (MRQ) 45.31 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 21.02 %

Management Effectiveness Current
Return On Assets (TTM) 34.69 %
Return On Investment (TTM) 40.68 %
Return On Equity (TTM) 62.22 %
Dividend Yield -
Pay out Ratio (TTM) -



Elite Pharmaceuticals Inc's Segments
Manufacturing    362.74 % of total Revenue
Licensing    2.6 % of total Revenue
Direct Sales to Wholesalers    160.19 % of total Revenue
Indirect Sales to Wholesalers    202.55 % of total Revenue
Manufacturing Fees    362.74 % of total Revenue
Scheduled Products Manufacturing Fees    347.17 % of total Revenue
Scheduled Products Licensing Fees    1.14 % of total Revenue
Un Scheduled Products Manufacturing Fees    15.57 % of total Revenue
Unscheduled Products Licensing Fees    1.46 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.